Wed, May 14, 11:19 AM (35 days ago)
**Summary of Centessa Pharmaceuticals plc (CNTA) Q1 2025 Financial Health and Performance:** **Revenue and Profit Margins:** - **Revenue:** $15.0 million from a license agreement with Genmab. - **Net Loss:** $26.1 million, a decrease from $38.0 million in Q1 2024. - **Operating Expenses:** $30.8 million, down from $36.1 million in Q1 2024. - **Interest Income:** $7.9 million, up from $2.6 million in Q1 2024. - **Interest Expense:** $2.9 million, slightly higher than $2.5 million in Q1 2024. **Cash Flow:** - **Net Cash Used in Operating Activities:** $57.2 million, up from $37.3 million in Q1 2024. - **Net Cash Used in Investing Activities:** $222.4 million, primarily due to investments in marketable securities. - **Net Cash Provided by Financing Activities:** $3.1 million, mainly from the ATM program. **Earnings Changes:** - **Earnings per Share (EPS):** Basic and diluted EPS was $(0.20), compared to $(0.38) in Q1 2024. **Quarterly Performance Discussion:** - **OX2R Agonist Program:** Continued development of ORX750, ORX142, and ORX489. - **LockBody Technology Platform:** License agreement with Genmab for research on up to three targets. - **Financial Health:** $424.9 million in cash, cash equivalents, and investments as of March 31, 2025. **Trends and Uncertainties:** - **Operational Risks:** Dependence on third-party manufacturers and clinical trial sites. - **Regulatory Risks:** Uncertainty in obtaining regulatory approvals. - **Financial Risks:** Need for substantial additional funding for development and commercialization. **Future Operations Impact:** - **Development Plans:** Continued investment in OX2R agonist and LockBody technology platforms. - **Commercialization:** Potential partnerships or internal capabilities for future product launches. **Note:** Amounts are usually in thousands.